Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 31;10(6):1287.
doi: 10.3390/biomedicines10061287.

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Martina Monti  1 , Susanna Lunardini  1 , Igino Andrea Magli  1 , Riccardo Campi  2 , Giulia Primiceri  1 , Francesco Berardinelli  1 , Daniele Amparore  3 , Daniela Terracciano  4 , Giuseppe Lucarelli  5 , Luigi Schips  1 , Matteo Ferro  6 , Michele Marchioni  1
Affiliations
Review

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Martina Monti et al. Biomedicines. .

Abstract

Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of the current knowledge of miRNAs as predictors of treatment resistance. A systematic review of the literature was carried out in January 2022 following the PICO methodology. Overall, we included seven studies-four testing plasmatic miRNAs, two exosomal miRNAs, and one urinary miRNA. A total of 789 patients were included (354 for plasmatic miRNAs, 366 for urinary miRNAs, and 69 for exosomal miRNAs). Several miRNAs were tested within the included studies, but six plasmatic (miR9-5-p¸ miR-192, miR193-3p, miR-501-3p¸ miR-221, miR-376b-3p) one urinary (miR-30a-5p), and three exosomal (miR-35-5p, miR-301a-3p, miR-1293) were associated with resistance to systemic treatments or treatment failure in mRCC patients. Results showed a fair accuracy of these biomarkers in predicting treatment resistance and overall survival. However, to date, the biomarkers tested have not been validated and their clinical uses are not recommended. Nevertheless, the literature results are encouraging; future large clinical trials are warranted to validate the effectiveness of these tools in clinical decision-making.

Keywords: advanced renal cell carcinoma (mRCC); exosomal; immunotherapy; liquid biopsy; metastatic; miRNA; plasmatic; tyrosine kinase inhibitor; urinary.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The PRISMA flowchart graphically depicts the selection of the study flow.
See this image and copyright information in PMC

References

    1. Znaor A., Lortet-Tieulent J., Laversanne M., Jemal A., Bray F. International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality. Eur. Urol. 2015;67:519–530. doi: 10.1016/j.eururo.2014.10.002. - DOI - PubMed
    1. Chow W.-H., Dong L.M., Devesa S.S. Epidemiology and Risk Factors for Kidney Cancer. Nat. Rev. Urol. 2010;7:245–257. doi: 10.1038/nrurol.2010.46. - DOI - PMC - PubMed
    1. Bandini M., Smith A., Marchioni M., Pompe R.S., Martel T.F., Cindolo L., Montorsi F., Shariat S.F., Briganti A., Kapoor A., et al. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clin. Genitourin. Cancer. 2018;16:176–183. doi: 10.1016/j.clgc.2018.01.003. - DOI - PubMed
    1. Hsieh J.J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal Cell Carcinoma. Nat. Rev. Dis. Primers. 2017;3:17009. doi: 10.1038/nrdp.2017.9. - DOI - PMC - PubMed
    1. Méjean A., Ravaud A., Thezenas S., Chevreau C., Bensalah K., Geoffrois L., Thiery-Vuillemin A., Cormier L., Lang H., Guy L., et al. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Eur. Urol. 2021;80:417–424. doi: 10.1016/j.eururo.2021.06.009. - DOI - PubMed